We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.43 | 0.33% | 131.15 | 131.91 | 130.13 | 130.13 | 7,757,432 | 01:00:00 |
From Apr 2022 to Apr 2024
14:04 ET -- Moderna Inc. and Merck & Co. Inc. are two of the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. A customized Moderna cancer vaccine combined with Merck's immunotherapy cancer drug Keytruda helped ward off the recurrence of the skin cancer melanoma after surgery in patients in a mid-stage clinical trial, the companies said. The combination cut patients' risk of relapse or death by about 44%, versus Keytruda alone, in the 150-volunteer study. The results suggest promise for an emerging but unproven class of vaccines that aim to treat diseases rather than prevent infections like typical shots. Moderna and Merck plan to run a larger study to confirm the combination's safety and efficacy next year. The companies said they will also test the combination in other types of cancers. Dow Jones & Co. owns Factiva.(jennifer.tershak@wsj.com)
(END) Dow Jones Newswires
December 13, 2022 14:18 ET (19:18 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
